Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 932632, 6 pages
http://dx.doi.org/10.1155/2008/932632
Review Article

PPAR 𝛾 , PTEN, and the Fight against Cancer

1Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
2Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
3Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA

Received 29 February 2008; Revised 9 July 2008; Accepted 7 October 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Rosemary E. Teresi and Kristin A. Waite. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Mueller, P. Sarraf, P. Tontonoz et al., “Terminal differentiation of human breast cancer through PPARγ,” Molecular Cell, vol. 1, no. 3, pp. 465–470, 1998. View at Publisher · View at Google Scholar
  2. C. Eng, “Will the real Cowden syndrome please stand up: revised diagnostic criteria,” Journal of Medical Genetics, vol. 37, no. 11, pp. 828–830, 2000. View at Publisher · View at Google Scholar
  3. C. Eng, “Genetics of Cowden syndrome: through the looking glass of oncology,” International Journal of Oncology, vol. 12, no. 3, pp. 701–710, 1998. View at Google Scholar
  4. K. A. Waite and C. Eng, “Protean PTEN: form and function,” The American Journal of Human Genetics, vol. 70, no. 4, pp. 829–844, 2002. View at Publisher · View at Google Scholar · View at PubMed
  5. D. Liaw, D. J. Marsh, J. Li et al., “Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome,” Nature Genetics, vol. 16, no. 1, pp. 64–67, 1997. View at Publisher · View at Google Scholar · View at PubMed
  6. D. J. Marsh, J. B. Kum, K. L. Lunetta et al., “PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome,” Human Molecular Genetics, vol. 8, no. 8, pp. 1461–1472, 1999. View at Publisher · View at Google Scholar
  7. P. M. Witman, “More than just a bump: the hamartoma syndromes,” Advances in Dermatology, vol. 22, pp. 157–180, 2006. View at Publisher · View at Google Scholar
  8. K. M. Zbuk and C. Eng, “Cancer phenomics: RET and PTEN as illustrative models,” Nature Reviews Cancer, vol. 7, no. 1, pp. 35–45, 2007. View at Publisher · View at Google Scholar · View at PubMed
  9. L. A. G. Ries, M. P. Eisner, C. L. Kosary et al., SEER Cancer Statistics Review, 1975–2000, National Cancer Institute, Bethesda, Md, USA, 2003.
  10. R. Pilarski and C. Eng, “Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome,” Journal of Medical Genetics, vol. 41, no. 5, pp. 323–326, 2004. View at Publisher · View at Google Scholar
  11. X.-P. Zhou, K. A. Waite, R. Pilarski et al., “Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway,” The American Journal of Human Genetics, vol. 73, no. 2, pp. 404–411, 2003. View at Publisher · View at Google Scholar
  12. S. M. Planchon, K. A. Waite, and C. Eng, “The nuclear affairs of PTEN,” Journal of Cell Science, vol. 121, no. 3, pp. 249–253, 2008. View at Publisher · View at Google Scholar · View at PubMed
  13. V. Stambolic, D. MacPherson, D. Sas et al., “Regulation of PTEN transcription by p53,” Molecular Cell, vol. 8, no. 2, pp. 317–325, 2001. View at Publisher · View at Google Scholar
  14. T. Virolle, E. D. Adamson, V. Baron et al., “The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling,” Nature Cell Biology, vol. 3, no. 12, pp. 1124–1128, 2001. View at Publisher · View at Google Scholar · View at PubMed
  15. M. G. Pezzolesi, K. M. Zbuk, K. A. Waite, and C. Eng, “Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome,” Human Molecular Genetics, vol. 16, no. 9, pp. 1058–1071, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. J. T. Whelan, S. L. Forbes, and F. E. Bertrand, “CBF-1 (RBP-Jκ) binds to the PTEN promoter and regulates PTEN gene expression,” Cell Cycle, vol. 6, no. 1, pp. 80–84, 2007. View at Google Scholar
  17. B. Han, Z. Dong, Y. Liu, Q. Chen, K. Hashimoto, and J.-T. Zhang, “Regulation of constitutive expression of mouse PTEN by the 5-untranslated region,” Oncogene, vol. 22, no. 34, pp. 5325–5337, 2003. View at Publisher · View at Google Scholar · View at PubMed
  18. K. Hettinger, F. Vikhanskaya, M. K. Poh et al., “c-Jun promotes cellular survival by suppression of PTEN,” Cell Death & Differentiation, vol. 14, no. 2, pp. 218–229, 2007. View at Publisher · View at Google Scholar · View at PubMed
  19. K. M. Vasudevan, S. Gurumurthy, and V. M. Rangnekar, “Suppression of PTEN expression by NF-κB prevents apoptosis,” Molecular and Cellular Biology, vol. 24, no. 3, pp. 1007–1021, 2004. View at Publisher · View at Google Scholar
  20. L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and C. H. Macphee, “Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN,” Current Biology, vol. 11, no. 10, pp. 764–768, 2001. View at Publisher · View at Google Scholar
  21. R. E. Teresi, C.-W. Shaiu, C.-S. Chen, V. K. Chatterjee, K. A. Waite, and C. Eng, “Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone,” International Journal of Cancer, vol. 118, no. 10, pp. 2390–2398, 2006. View at Publisher · View at Google Scholar · View at PubMed
  22. D. Bonofiglio, S. Gabriele, S. Aquila et al., “Estrogen receptor α binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor γ signaling in breast cancer cells,” Clinical Cancer Research, vol. 11, no. 17, pp. 6139–6147, 2005. View at Publisher · View at Google Scholar · View at PubMed
  23. W. Zhang, N. Wu, Z. Li, L. Wang, J. Jin, and X.-L. Zha, “PPARγ activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404,” Cancer Biology and Therapy, vol. 5, no. 8, pp. 1008–1014, 2006. View at Google Scholar
  24. S. Y. Lee, G. Y. Hur, K. H. Jung et al., “PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression,” Lung Cancer, vol. 51, no. 3, pp. 297–301, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. S. Han and J. Roman, “Rosiglitazone suppresses human lung carcinoma cell growth through PPARγ-dependent and PPARγ-independent signal pathways,” Molecular Cancer Therapeutics, vol. 5, no. 2, pp. 430–437, 2006. View at Publisher · View at Google Scholar · View at PubMed
  26. A. Aiello, G. Pandini, F. Frasca et al., “Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells,” Endocrinology, vol. 147, no. 9, pp. 4463–4475, 2006. View at Publisher · View at Google Scholar · View at PubMed
  27. Y. Chen, S.-M. Wang, J.-C. Wu, and S.-H. Huang, “Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line,” Journal of Cellular Biochemistry, vol. 98, no. 4, pp. 1021–1035, 2006. View at Publisher · View at Google Scholar · View at PubMed
  28. P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPARγ associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999. View at Publisher · View at Google Scholar
  29. E. A. Thompson, “PPARγ physiology and pathology in gastrointestinal epithelial cells,” Molecules and Cells, vol. 24, no. 2, pp. 167–176, 2007. View at Google Scholar
  30. F. Bogazzi, F. Ultimieri, F. Raggi et al., “Peroxisome proliferator activated receptor γ expression is reduced in the colonic mucosa of acromegalic patients,” The Journal of Clinical Endocrinology & Metabolism, vol. 87, no. 5, pp. 2403–2406, 2002. View at Publisher · View at Google Scholar
  31. L. Dubuquoy, S. Dharancy, S. Nutten, S. Pettersson, J. Auwerx, and P. Desreumaux, “Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases,” The Lancet, vol. 360, no. 9343, pp. 1410–1418, 2002. View at Publisher · View at Google Scholar · View at PubMed
  32. T. Ikezoe, C. W. Miller, S. Kawano et al., “Mutational analysis of the peroxisome proliferator-activated receptor γ in human malignancies,” Cancer Research, vol. 61, no. 13, pp. 5307–5310, 2001. View at Google Scholar
  33. J. Kohlroser, J. Mathai, J. Reichheld, B. F. Banner, and H. L. Bonkovsky, “Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration,” American Journal of Gastroenterology, vol. 95, no. 1, pp. 272–276, 2000. View at Publisher · View at Google Scholar
  34. S. E. Nissen, “Perspective: effect of rosiglitazone on cardiovascular outcomes,” Current Cardiology Reports, vol. 9, no. 5, pp. 343–344, 2007. View at Publisher · View at Google Scholar
  35. M. Banning, “Symptoms and treatments of polycystic ovary syndrome,” British Journal of Nursing, vol. 15, no. 12, pp. 635–639, 2006. View at Google Scholar
  36. L. D. Yee, N. Williams, P. Wen et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers,” Clinical Cancer Research, vol. 13, no. 1, pp. 246–252, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. R. E. Teresi, S. M. Planchon, K. A. Waite, and C. Eng, “Regulation of the PTEN promoter by statins and SREBP,” Human Molecular Genetics, vol. 17, no. 7, pp. 919–928, 2008. View at Publisher · View at Google Scholar · View at PubMed